sabizabulin (Veru-111)
Jump to navigation
Jump to search
Indications
- investigational agent for treatment of severe Covid-19
Dosage
Clinical significance
- 55% reduction in deaths vs placebo in hospitalized patients with moderate- severe Covid-19*
* both treatment groups were allowed to receive standard of care including remdesivir, dexamethasone, anti-IL-6 receptor antibodies, & JAK inhibitors
Mechanism of action
- disrupts microtubules
More general terms
References
- ↑ Ingram I Whopping Mortality Benefit in Severe COVID Trial. Oral sabizabulin showed 55% reduction in risk for death in hospitalized patients. MedPage Today July 7, 2022 https://www.medpagetoday.com/infectiousdisease/covid19/99610
Barnette KG, Gordon MS, Rodriguez D Oral Sabizabulin for High-Risk, Hospitalized Adults with Covid-19: Interim Analysis. NEJM Evidence. 2022. July 6. PMID: https://www.ncbi.nlm.nih.gov/pubmed/38319812 DOI: 10.1056/EVIDoa2200145 https://evidence.nejm.org/doi/full/10.1056/EVIDoa2200145
Veru Veru's Novel COVID-19 Drug Candidate Reduces Deaths by 55% in Hospitalized Patients in Interim Analysis of Phase 3 Study; Independent Data Monitoring Committee Halts Study Early for Overwhelming Efficacy. https://verupharma.com/news/verus-novel-covid-19-drug-candidate-reduces-deaths-by-55-in-hospitalized-patients-in-interim-analysis-of-phase-3-study-independent-data-monitoring-committee-halts-study-early-for-overwhelmin/